A5415 A Limited-Center, Prospective, Double-Blind, Placebo-Controlled Study To Evaluate The Effects Of Cenicriviroc Mesylate On Arterial Inflammation In People Living With Hiv
Posted Date: Apr 25, 2023
- Investigator: Moises Huaman
- Specialties:
- Type of Study: Drug
A Limited-Center, Prospective, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living with HIV
Criteria:
Have Hiv Infection Current Hiv Rna <20 Current Cd4+ >200 On Stable Antiretroviral Therapy No Myocardial Infarction Or Unstable Angina Within 90 Days Hepatitis C Negative No Untreated Hepatitis B No Active Malignancy (Cancer) No Change In Statin Therapy For 90 Days No History Of Radiation Therapy Not Currently Pregnant, Planning To Become Pregnant Or Breastfeeding.
Keywords:
Hiv, Inflammation
For More Information:
Michelle Saemann
513-584-2245
saemanmd@ucmail.uc.edu